Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes

Donald B. Fuller,Aaron D. Falchook,Tami Crabtree,Brent L. Kane,Clinton A. Medbery,K. Underhill,James R. Gray,Anuj V. Peddada,Ronald C. Chen

European Urology Oncology（2018）

引用 45|浏览16

暂无评分

摘要

The 5-yr results from this multicenter phase 2 trial show that a novel four-fraction stereotactic body radiotherapy regimen is safe and effective for properly selected patients with low- or intermediate-risk prostate cancer.

查看译文

关键词

Prostate cancer,Radiation therapy,Stereotactic body radiotherapy,Outcomes,Hypofractionation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要